The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a significant shift in corporate healthcare strategies, some US employers are planning to drop insurance coverage for GLP-1 obesity medications by 2027. This move is primarily driven by surging utilization rates that are straining corporate health plan budgets. According to reports, the sheer volume of employees accessing these treatments is now offsetting any savings gained from lower per-unit drug prices.
These plans pose a challenge to industry leaders Eli Lilly and Novo Nordisk, as the US market remains the primary revenue driver for these high-demand drugs. Per market data, Eli Lilly (LLY) closed at $1136.37 on June 10, 2026, while Novo Nordisk (NVO) closed at $42.81. Analysts suggest that a broader retreat in employer coverage could dampen long-term volume projections in the world's most lucrative pharmaceutical market.
Sign in to access this content
Sign InTraders should watch key support levels for LLY at $1133.53 and NVO at $41.66, based on the lows recorded at the close of June 10, 2026. Looking ahead, upcoming US employment data and Fed speeches on the economic calendar will be critical for assessing consumer health and broader spending trends that may impact private healthcare allocations.